背景:结肠癌(coloncancer,CC)是世界范围内常见的恶性肿瘤。在这项研究中,研究了来自癌症基因组图谱(TCGA)的473例结肠癌和41例CC患者的邻近组织中N6-甲基腺苷相关的长链非编码RNA(m6A相关的lncRNA)。方法:采用Pearson相关性分析检测m6A相关的lncRNAs,并进行单变量Cox回归分析以筛选38个预后m6A相关lncRNAs。对38个预后lncRNAs进行了最小绝对收缩和选择算子(LASSO)回归分析,以在CC中开发14个m6A相关lncRNAs预后标签(m6A-LPS)。使用Kaplan-Meier和接收器工作特征(ROC)曲线评价m6A-LPS的可用性。结果:三种不同N阶段的m6A修饰模式,生存时间,并确定了免疫景观。已经发现m6A-LPS,它基于14个m6A相关的lncRNAs(TNFRSF10A-AS1,AC245041.1,AL513550.1,UTAT33,SNHG26,AC092944.1,ITGB1-DT,AL138921.1,AC099850.3,NCBP2-AS1,AL137782.1,AC073896.3,AP006621.2,AC147651.1),可能代表一个新的,具有巨大潜力的有前途的生物标志物。根据存活率重新评估,临床特征,肿瘤浸润免疫细胞,与免疫检查点抑制剂(ICIs)相关的生物标志物,和化疗药物疗效。已发现m6A-LPS是评估CC患者预后的新型潜在且有希望的预测因子。结论:这项研究表明,风险特征是一个有前途的预测指标,可以在CC治疗中提供更准确的临床应用,并为临床医生提供有效的治疗策略。
Background: Colon cancer (CC) is a prevalent malignant tumor that affects people all around the world. In this study, N6-methylandenosine-related long non-coding RNAs (m6A-related lncRNAs) in 473 colon cancers and 41 adjacent tissues of CC patients from The Cancer Genome Atlas (TCGA) were investigated. Method: The Pearson correlation analysis was conducted to examine the m6A-related lncRNAs, and the univariate Cox regression analysis was performed to screen 38 prognostic m6A-related lncRNAs. The least absolute shrinkage and selection operator (LASSO) regression analysis were carried out on 38 prognostic lncRNAs to develop a 14 m6A-related lncRNAs prognostic signature (m6A-LPS) in CC. The availability of the m6A-LPS was evaluated using the Kaplan-Meier and Receiver Operating Characteristic (ROC) curves. Results: Three m6A modification patterns with significantly different N stages, survival time, and immune landscapes were identified. It has been discovered that the m6A-LPS, which is based on 14 m6A-related lncRNAs (TNFRSF10A-AS1, AC245041.1, AL513550.1, UTAT33, SNHG26, AC092944.1, ITGB1-DT, AL138921.1, AC099850.3, NCBP2-AS1, AL137782.1, AC073896.3, AP006621.2, AC147651.1), may represent a new, promising biomarker with great potential. It was re-evaluated in terms of survival rate, clinical features, tumor infiltration immune cells, biomarkers related to Immune Checkpoint Inhibitors (ICIs), and chemotherapeutic drug efficacy. The m6A-LPS has been revealed to be a novel potential and promising predictor for evaluating the prognosis of CC patients. Conclusion: This study revealed that the risk signature is a promising predictive indicator that may provide more accurate clinical applications in CC therapeutics and enable effective therapy strategies for clinicians.